| TRAIL and chemotherapeutic drugs in cancer therapy. | |
| | |
MedLine Citation:
|
PMID: 15110186 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL/Apo2L) is a recently identified member of the TNF ligand family that selectively induces apoptosis in tumor cells in vitro and in vivo but not in most normal cells. Chemotherapeutic drugs induce apoptosis and the upregulation of death receptors or activation of intracellular signaling pathways of TRAIL. Numerous chemotherapeutic drugs have been shown to sensitize tumor cells to TRAIL-mediated apoptosis. Studies from our laboratory have also shown that TRAIL-resistant renal cell carcinoma, prostate gland cancer, and bladder cancer cells are sensitized by subtoxic concentrations of chemotherapeutic drugs including doxorubicin, epirubicin, pirarubicin, and cisplatin. TRAIL, particularly in combination with chemotherapeutic agents, is thus potentially promising in the treatment of cancer. This review addresses the putative role of TRAIL in cancer treatment and discusses the molecular basis of the synergistic effect of TRAIL and chemotherapeutic drugs. |
| | |
Authors:
|
Xiu-Xian Wu; Osamu Ogawa; Yoshiyuki Kakehi |
Related Documents
:
|
9264326 - Differential regulation of phospholipase a2 in human leukemia cells by the etherphospho... 15259086 - Effect of octreotide on human pancreatic cancer cells after transfected with somatostat... 12697056 - Staphylococcus aureus - induced tumor necrosis factor - related apoptosis - inducing li... 9114456 - Tumor cell cytolysis mediated by valorphin, an opioid-like fragment of hemoglobin beta-... 21590006 - Analysis of the proliferative and phenotypic properties of tumor infiltrating lymphocyt... 19201456 - Organ-sparing microsurgical resection of incidental testicular tumors plus microdissect... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Vitamins and hormones Volume: 67 ISSN: 0083-6729 ISO Abbreviation: Vitam. Horm. Publication Date: 2004 |
Date Detail:
|
Created Date: 2004-04-27 Completed Date: 2004-07-07 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 0413601 Medline TA: Vitam Horm Country: United States |
Other Details:
|
Languages: eng Pagination: 365-83 Citation Subset: IM |
Affiliation:
|
Department of Urology, Kagawa University, Kagawa 761-0793, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adaptor Proteins, Signal Transducing* Animals Antineoplastic Agents* / therapeutic use Apoptosis Apoptosis Regulatory Proteins Carrier Proteins / metabolism Caspase 8 Caspases / metabolism Cytotoxicity, Immunologic Drug Synergism Fas-Associated Death Domain Protein Humans Membrane Glycoproteins* / physiology, therapeutic use Neoplasms / drug therapy* Receptors, Tumor Necrosis Factor Signal Transduction TNF-Related Apoptosis-Inducing Ligand Tumor Necrosis Factor-alpha* / physiology, therapeutic use |
| Chemical | |
Reg. No./Substance:
|
0/Adaptor Proteins, Signal Transducing; 0/Antineoplastic Agents; 0/Apoptosis Regulatory Proteins; 0/Carrier Proteins; 0/FADD protein, human; 0/Fas-Associated Death Domain Protein; 0/Membrane Glycoproteins; 0/Receptors, Tumor Necrosis Factor; 0/TNF-Related Apoptosis-Inducing Ligand; 0/TNFSF10 protein, human; 0/Tumor Necrosis Factor-alpha; EC 3.4.22.-/CASP8 protein, human; EC 3.4.22.-/Caspase 8; EC 3.4.22.-/Caspases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Potential for TRAIL as a therapeutic agent in ovarian cancer.
Next Document: Additive effects of TRAIL and paclitaxel on cancer cells: implications for advances in cancer therap...